


"The annual prevalence of DFUs is estimated to be 4–10%, and the risk of development of these ulcers in diabetics is estimated to be anywhere from 15% to 25%"

WE'RE CHANGING THE DYNAMICS OF WOUND HEALING

Diabetic Foot Ulcer

Richard A. Schilling, D.P.M., Scott R. Littrell, D.P.M.



Day 0

Open wound



Day 20

Continued progressive healing
[87% reduction]



Day 34

Complete wound closure

IN AN EVALUATION OF 12 DFU'S

MEDIAN WOUND CLOSURE

83%

WITHIN 4 WEEKS

MEDIAN NUMBER OF WEEKS

6

TO WOUND CLOSURE

MEDIAN APPLICATIONS

3

TO WOUND CLOSURE



PHOENIX™
WOUND MATRIX

Powered by Electrospun
Synthetic Polymer Technology

MEDIAN

WE'RE CHANGING THE DYNAMICS OF WOUND HEALING

| | All Cases | Pressure Ulcer | DFU | Chronic Vascular | Surgical Wound | Trauma Wound | Complex | Complex Acute |
|--------------------------------------|-----------|----------------|------|------------------|----------------|--------------|---------|---------------|
| Patients | 34 | 4 | 11 | 12 | 1 | 3 | 2 | 1 |
| Wounds | 46 | 4 | 12 | 24 | 1 | 3 | 2 | 1 |
| Positive change in tissue appearance | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
| % Area Reduction at 4 weeks | 89% | 95% | 83% | 90% | 61% | 63% | 87% | 97% |
| % Area Reduction at 8 weeks | 98% | - | 98% | 86% | 80% | 97% | 92% | 100% |

POSTER PRESENTATION CASE SERIES SUMMARY

PERCENTAGE OF REDUCTION

100%
IN INFLAMMATION

MEDIAN WOUND CLOSURE

98%
WITHIN 8 WEEKS

MEDIAN NUMBER OF WEEKS

5
TO WOUND CLOSURE

MEDIAN APPLICATIONS

2
TO WOUND CLOSURE



PHOENIX™
WOUND MATRIX
Powered by Electrospun
Synthetic Polymer Technology

Addressing chronicity and persistent inflammation to accelerate wound healing outcomes

View entire case and additional data at: www.renovoderm.tech | *National average for CTP applications: 5-8


PHOENIX WOUND MATRIX™ is a sophisticated 3D electrospun synthetic polymer matrix designed to provide a microporous scaffold stimulus for tissue regeneration and repair of acute and chronic wounds, and burns.

- Engineered to mimic native ECM morphology
- Fiber diameters and porosity scientifically designed to stimulate pro-regenerative cellular function
- Comprised of bioresorbable synthetic polymers that degrade into α -hydroxy and fatty acids, known to aid in the wound healing process
 - Lowers pH to support a pro-healing wound environment^{1,2}
 - Supports lactate-mediated effects known to promote angiogenesis, oxygenation and accelerated wound healing³
- *In vitro* testing demonstrates a significant increase of cell proliferation with Phoenix Wound Matrix compared to TCP over 24 hours of culture⁴
- Case studies demonstrate consistent healing trajectories through to wound closure
- Easy to apply, non-side specific conformable matrix
- 2-year shelf life
- Offers a first-line, cost-effective synthetic polymer solution to optimize your wound healing outcomes




SIZING AND REIMBURSEMENT

PHOENIX™ Wound Matrix



PHOENIX™ Wound Matrix Fenestrated



HCPCS - C1849
Skin substitute,
synthetic, resorbable
per sq. cm.

RENOVODERM

1. Nagoba BS, Suryawanshi NM, Wadher B, Selkar S. Acidic Environment and Wound Healing: A Review. *Wounds*. 2015;27(1):5-11.
 2. Jones EM, Cochrane CA, Percival SL. The Effect of pH on the Extracellular Matrix and Biofilms. *Advances in Wound Care*. 2015;4(7):431-439. doi:10.1089/wound.2014.0538.
 3. Porporato PE, Payen VL, Saedeleer CJD, et al. Lactate stimulates angiogenesis and accelerates the healing of superficial and ischemic wounds in mice. *Angiogenesis*. 2012;15(4):581-592. doi:10.1007/s10456-012-9282-0.
 4. Data on file, DOC-348
- ★ Advanced wound care device, also known as cellular and/or tissue-based product (CTP) or skin substitute.
† All claims supported by human use studies, Good Lab Practice (GLP), porcine animal study and veterinary case studies



**PHOENIX™
WOUND MATRIX**
Powered by Electrospun
Synthetic Polymer Technology